Xml Financial, LLC Macrogenics Inc Transaction History

Xml Financial, LLC

$1.13 Billion
Q2 2025

A detailed history of Xml Financial, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Xml Financial, LLC holds 32,336 shares of MGNX stock, worth $52,060. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,336

Previous 19,169 68.69%

Holding current value

$52,060

Previous $24,000 62.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 17, 2025	BUY	$1.06 - $1.79 $13,957 - $23,568	13,167 Added 68.69%	32,336 $39,000
Q1 2025 Apr 22, 2025	SELL	$1.26 - $3.49 $5,040 - $13,960	-4,000 Reduced 17.26%	19,169 $24,000
Q4 2024 Jan 17, 2025	BUY	$3.18 - $4.46 $17,709 - $24,837	5,569 Added 31.64%	23,169 $75,000
Q3 2024 Nov 01, 2024	BUY	$3.0 - $5.55 $21,000 - $38,850	7,000 Added 66.04%	17,600 $57,000
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $17,920 - $40,440	-4,000 Reduced 27.4%	10,600 $101,000
Q3 2023 Nov 06, 2023	SELL	$4.48 - $6.19 $448 - $619	-100 Reduced 0.68%	14,600 $68,000
Q4 2022 Feb 09, 2023	SELL	$3.34 - $6.98 $33,316 - $69,625	-9,975 Reduced 40.43%	14,700 $98,000
Q3 2022 Nov 04, 2022	BUY	$3.01 - $5.22 $6,694 - $11,609	2,224 Added 9.91%	24,675 $85,000
Q2 2022 Aug 01, 2022	BUY	$2.25 - $9.99 $7,422 - $32,957	3,299 Added 17.23%	22,451 $66,000
Q1 2022 May 02, 2022	BUY	$8.12 - $16.9 $28,257 - $58,811	3,480 Added 22.21%	19,152 $169,000
Q4 2021 Feb 01, 2022	BUY	$15.91 - $21.88 $249,341 - $342,903	15,672 New	15,672 $252,000

Others Institutions Holding MGNX

# of Institutions

126

Shares Held

53.3M

Call Options Held

45.1K

Put Options Held

143K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $98.9M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xml Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Xml Financial, LLC with notifications on news.

Account

Xml Financial, LLC Macrogenics Inc Transaction History